Literature DB >> 23447360

Vascular extracellular signal-regulated kinase mediates migraine-related sensitization of meningeal nociceptors.

XiChun Zhang1, Vanessa Kainz, Jun Zhao, Andrew M Strassman, Dan Levy.   

Abstract

OBJECTIVE: To examine changes in the response properties of meningeal nociceptors that might lead to migraine pain and examine endogenous processes that could play a role in mediating them using a clinically relevant model of migraine triggering, namely infusion of the nitric oxide (NO) donor nitroglycerin (NTG).
METHODS: Single-unit recordings made in the trigeminal ganglion of rats were used to test changes in the activity and mechanosensitivity of meningeal nociceptors in response to administration of the migraine trigger NTG or another NO donor S-nitroso-N-acetyl-DL-penicillamine (SNAP) at doses relevant to the human model of migraine headache. Immunohistochemistry and pharmacological manipulations were used to investigate the possible role of meningeal vascular signaling in mediating the responses of meningeal nociceptors to NO.
RESULTS: Infusion of NTG promoted a delayed and robust increase in the mechanosensitivity of meningeal nociceptors, with a time course resembling the development of the delayed migraine headache. A similar sensitization was elicited by dural application of NTG and SNAP. NTG-evoked delayed meningeal nociceptor sensitization was associated with a robust extracellular signal-regulated kinase (ERK) phosphorylation in meningeal arteries. Pharmacological blockade of meningeal ERK phosphorylation inhibited the development of NTG-evoked delayed meningeal nociceptor sensitization.
INTERPRETATION: The development of delayed mechanical sensitization evoked by the migraine trigger NTG is potentially of great importance as the first finding of a neurophysiological correlate of migraine headache in meningeal nociceptors. The arterial ERK phosphorylation and its involvement in mediating the NTG-evoked delayed sensitization points to an important, yet unappreciated, role of the meningeal vasculature in the genesis of migraine pain.
© 2013 American Neurological Association.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23447360      PMCID: PMC3688635          DOI: 10.1002/ana.23873

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  58 in total

Review 1.  Examining the essence of migraine--is it the blood vessel or the brain? A debate.

Authors:  David W Dodick
Journal:  Headache       Date:  2008-04       Impact factor: 5.887

2.  Triptan-induced latent sensitization: a possible basis for medication overuse headache.

Authors:  Milena De Felice; Michael H Ossipov; Ruizhong Wang; Josephine Lai; Juliana Chichorro; Ian Meng; David W Dodick; Todd W Vanderah; Gregory Dussor; Frank Porreca
Journal:  Ann Neurol       Date:  2010-03       Impact factor: 10.422

3.  Calcitonin gene-related peptide receptor inhibition reduces neuronal activity induced by prolonged increase in nitric oxide in the rat spinal trigeminal nucleus.

Authors:  S Koulchitsky; M J M Fischer; K Messlinger
Journal:  Cephalalgia       Date:  2008-11-25       Impact factor: 6.292

4.  Cerebral ischemia induces microvascular pro-inflammatory cytokine expression via the MEK/ERK pathway.

Authors:  Aida Maddahi; Lars Edvinsson
Journal:  J Neuroinflammation       Date:  2010-02-26       Impact factor: 8.322

Review 5.  Migraine: where and how does the pain originate?

Authors:  Karl Messlinger
Journal:  Exp Brain Res       Date:  2009-03-14       Impact factor: 1.972

Review 6.  Origin of pain in migraine: evidence for peripheral sensitisation.

Authors:  Jes Olesen; Rami Burstein; Messoud Ashina; Peer Tfelt-Hansen
Journal:  Lancet Neurol       Date:  2009-07       Impact factor: 44.182

7.  Ongoing activity in trigeminal wide-dynamic range neurons is driven from the periphery.

Authors:  M Roch; K Messlinger; V Kulchitsky; O Tichonovich; O Azev; S Koulchitsky
Journal:  Neuroscience       Date:  2007-09-19       Impact factor: 3.590

8.  Migraine headache is not associated with cerebral or meningeal vasodilatation--a 3T magnetic resonance angiography study.

Authors:  G G Schoonman; J van der Grond; C Kortmann; R J van der Geest; G M Terwindt; M D Ferrari
Journal:  Brain       Date:  2008-05-23       Impact factor: 13.501

9.  Vasoactive intestinal peptide causes marked cephalic vasodilation, but does not induce migraine.

Authors:  A Rahmann; T Wienecke; J M Hansen; J Fahrenkrug; J Olesen; M Ashina
Journal:  Cephalalgia       Date:  2008-03       Impact factor: 6.292

10.  Enhanced expressions of microvascular smooth muscle receptors after focal cerebral ischemia occur via the MAPK MEK/ERK pathway.

Authors:  Aida Maddahi; Lars Edvinsson
Journal:  BMC Neurosci       Date:  2008-09-15       Impact factor: 3.288

View more
  23 in total

1.  Dissociation between CSD-Evoked Metabolic Perturbations and Meningeal Afferent Activation and Sensitization: Implications for Mechanisms of Migraine Headache Onset.

Authors:  Jun Zhao; Dan Levy
Journal:  J Neurosci       Date:  2018-04-27       Impact factor: 6.167

Review 2.  Nitric oxide signalling in the brain and its control of bodily functions.

Authors:  Konstantina Chachlaki; Vincent Prevot
Journal:  Br J Pharmacol       Date:  2019-09-08       Impact factor: 8.739

Review 3.  Targeted Nitric Oxide Synthase Inhibitors for Migraine.

Authors:  Amynah A Pradhan; Zachariah Bertels; Simon Akerman
Journal:  Neurotherapeutics       Date:  2018-04       Impact factor: 7.620

Review 4.  Modelling headache and migraine and its pharmacological manipulation.

Authors:  S E Erdener; T Dalkara
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

5.  Current understanding of trigeminal ganglion structure and function in headache.

Authors:  Karl Messlinger; Andrew F Russo
Journal:  Cephalalgia       Date:  2018-07-10       Impact factor: 6.292

Review 6.  Neurogenic inflammation and its role in migraine.

Authors:  Roshni Ramachandran
Journal:  Semin Immunopathol       Date:  2018-03-22       Impact factor: 9.623

Review 7.  Therapeutic use of botulinum toxin in migraine: mechanisms of action.

Authors:  Roshni Ramachandran; Tony L Yaksh
Journal:  Br J Pharmacol       Date:  2014-09       Impact factor: 8.739

Review 8.  Animal migraine models for drug development: status and future perspectives.

Authors:  Inger Jansen-Olesen; Peer Tfelt-Hansen; Jes Olesen
Journal:  CNS Drugs       Date:  2013-12       Impact factor: 5.749

Review 9.  Neurovascular contributions to migraine: Moving beyond vasodilation.

Authors:  Blaine Jacobs; Gregory Dussor
Journal:  Neuroscience       Date:  2016-06-14       Impact factor: 3.590

10.  Characterization of a mouse model of headache.

Authors:  Dongyue Huang; Lynn Ren; Chang-Shen Qiu; Ping Liu; Jonathan Peterson; Yuchio Yanagawa; Yu-Qing Cao
Journal:  Pain       Date:  2016-08       Impact factor: 7.926

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.